# Kathleen N. Moore

Source: https://onco.cc/people/kathleen-moore/  
OnCo record `kathleen-moore` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led SOLO-1 and MIRASOL, which gave ovarian cancer a maintenance PARP inhibitor and its first ADC with a survival benefit.

## Summary

Kathleen Moore was principal investigator of SOLO-1, which showed two years of maintenance olaparib after first-line chemotherapy dramatically extends progression-free survival in BRCA-mutant ovarian cancer and later showed a survival benefit, and of MIRASOL, which showed mirvetuximab soravtansine improves survival in platinum-resistant folate receptor alpha-high disease, the first ADC to do so in ovarian cancer. She is associate director of the GOG Partners programme and leads early-phase gynaecological trials.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: ovarian; parp; adc; trialist
- Role: Associate Director of Clinical Research, Stephenson Cancer Center, University of Oklahoma
- Specialisms: Ovarian cancer; PARP inhibitors; Antibody-drug conjugates; Early drug development

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Moore%20KN%5BAuthor%5D%20ovarian%20olaparib%20OR%20mirvetuximab

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [Folate receptor alpha](https://onco.cc/targets/folr1/), [PARP](https://onco.cc/targets/parp/)
- drugs: [Mirvetuximab soravtansine](https://onco.cc/drugs/mirvetuximab-soravtansine/), [Olaparib](https://onco.cc/drugs/olaparib/)
- companies: [GOG Foundation](https://onco.cc/companies/gog-foundation/)
- institutions: [Stephenson Cancer Center, OU Health](https://onco.cc/institutions/stephenson-oklahoma/)
- trials: [MIRASOL / GOG-3045](https://onco.cc/trials/mirasol/), [SOLO-1](https://onco.cc/trials/solo-1/)
- key papers: [SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer](https://onco.cc/key-papers/paper-solo-1-nejm-2018/)

---
JSON: https://onco.cc/api/v1/entities/kathleen-moore.json